DNA2: A Promising Drug Target and Biomarker (G1763)

Target Name: DNA2

NCBI ID: G1763

DNA2

DNA2: A Promising Drug Target and Biomarker

DNA2 is a novel DNA-binding protein that was discovered through a combination of biochemical, cellular, and structural studies. DNA2 has been shown to play a critical role in various cellular processes, including DNA replication, repair, and metabolism. Its unique structure and function have led to the speculation that DNA2 may be a drug target or biomarker. In this article, we will explore the potential of DNA2 as a drug target and biomarker, as well as its current state of research and development.

The Discovery of DNA2

DNA2 was first identified through a screening experiment for DNA-binding proteins using the DNA-binding domain of the protein Max. Max is a core component of the machinery that ensures the proper functioning of DNA replication in eukaryotic cells. The screening experiment identified a protein that was able to bind to the DNA-binding domain of Max with high affinity.

To further investigate the protein, its structure was determined through a combination of biochemical and structural studies. The protein was shown to have a unique structure that included a long N-terminal region, a middle transmembrane region, and a C-terminal region that included a conserved protein-coding region and several potential binding sites.

Functional Studies

Functional studies have shown that DNA2 plays a critical role in various cellular processes. In addition to its role in DNA replication and repair, DNA2 has also been shown to be involved in metabolism and cell signaling.

For example, DNA2 has been shown to play a role in the replication of DNA in cancer cells. In fact, studies have shown that inhibiting DNA2 can lead to a reduction in the growth of cancer cells. This is because DNA2 is involved in the regulation of DNA replication, and its inhibition can lead to the loss of this critical process.

Another example of DNA2's function is its role in cell signaling. Studies have shown that DNA2 can interact with various signaling proteins, including T-cell factor 4 (TGF-4). This interaction is important for the regulation of cell signaling and has been implicated in various diseases, including cancer.

Potential Drug Target

The unique structure and function of DNA2 make it a promising drug target. The protein has been shown to interact with various signaling proteins and has been shown to play a role in the regulation of cellular processes. This suggests that inhibiting DNA2 may have a variety of potential therapeutic applications.

In addition to its potential therapeutic applications, DNA2 has also been shown to be a potential biomarker. The protein has been shown to have a unique expression pattern in various tissues and has been shown to be involved in the regulation of cellular processes. This suggests that its expression may be a useful biomarker for the diagnosis and treatment of various diseases.

Current State of Research and Development

Current research and development efforts are focused on the characterization of DNA2 as a drug target and biomarker. This includes studies to determine the full range of its functions, as well as its potential therapeutic applications.

One of the main areas of research is the characterization of DNA2's binding affinity and the identification of potential binding sites. This information will be used to determine the most promising targets for further study and development.

Another area of research is the development of small molecules that can inhibit DNA2 and its functions. This research is focused on identifying compounds that can specifically target DNA2 and have the potential to be therapeutic agents.

Conclusion

In conclusion, DNA2 is a novel and promising drug target and biomarker. Its unique structure and function have led to a wealth of research and development opportunities. Further studies are needed to fully understand its potential therapeutic applications and to identify compounds that can inhibit its functions. With continued research and development, DNA2 has the potential to become a valuable tool for the diagnosis and treatment of various diseases.

Protein Name: DNA Replication Helicase/nuclease 2

Functions: Key enzyme involved in DNA replication and DNA repair in nucleus and mitochondrion. Involved in Okazaki fragments processing by cleaving long flaps that escape FEN1: flaps that are longer than 27 nucleotides are coated by replication protein A complex (RPA), leading to recruit DNA2 which cleaves the flap until it is too short to bind RPA and becomes a substrate for FEN1. Also involved in 5'-end resection of DNA during double-strand break (DSB) repair: recruited by BLM and mediates the cleavage of 5'-ssDNA, while the 3'-ssDNA cleavage is prevented by the presence of RPA. Also involved in DNA replication checkpoint independently of Okazaki fragments processing. Possesses different enzymatic activities, such as single-stranded DNA (ssDNA)-dependent ATPase, 5'-3' helicase and endonuclease activities. While the ATPase and endonuclease activities are well-defined and play a key role in Okazaki fragments processing and DSB repair, the 5'-3' DNA helicase activity is subject to debate. According to various reports, the helicase activity is weak and its function remains largely unclear. Helicase activity may promote the motion of DNA2 on the flap, helping the nuclease function

The "DNA2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DNA2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets